IRIS
DE LAURENTIIS, MICHELINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.556
EU - Europa 5.742
NA - Nord America 5.701
SA - Sud America 1.158
AF - Africa 186
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 21.355
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.421
SG - Singapore 4.569
RU - Federazione Russa 2.798
CN - Cina 1.830
HK - Hong Kong 952
BR - Brasile 929
IT - Italia 872
VN - Vietnam 603
DE - Germania 543
FI - Finlandia 293
NL - Olanda 288
UA - Ucraina 186
IE - Irlanda 185
GB - Regno Unito 171
IN - India 162
CA - Canada 152
KR - Corea 117
AR - Argentina 105
FR - Francia 95
MX - Messico 81
SE - Svezia 81
AT - Austria 66
ZA - Sudafrica 65
BD - Bangladesh 52
PL - Polonia 42
CI - Costa d'Avorio 40
ID - Indonesia 40
EC - Ecuador 32
CO - Colombia 27
ES - Italia 27
IQ - Iraq 26
PK - Pakistan 22
JP - Giappone 20
TR - Turchia 20
PY - Paraguay 19
CL - Cile 14
VE - Venezuela 14
CZ - Repubblica Ceca 13
JO - Giordania 13
TN - Tunisia 13
UZ - Uzbekistan 12
MA - Marocco 11
SA - Arabia Saudita 11
BE - Belgio 10
LT - Lituania 10
NP - Nepal 10
IR - Iran 9
TW - Taiwan 9
DO - Repubblica Dominicana 8
JM - Giamaica 8
KE - Kenya 8
KZ - Kazakistan 8
UY - Uruguay 8
IL - Israele 7
RO - Romania 7
AL - Albania 6
CH - Svizzera 6
DZ - Algeria 6
EG - Egitto 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
AM - Armenia 5
AU - Australia 5
BH - Bahrain 5
BZ - Belize 5
ET - Etiopia 5
HN - Honduras 5
MY - Malesia 5
BG - Bulgaria 4
GE - Georgia 4
GT - Guatemala 4
HR - Croazia 4
LA - Repubblica Popolare Democratica del Laos 4
LV - Lettonia 4
MD - Moldavia 4
OM - Oman 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
CG - Congo 3
KH - Cambogia 3
LB - Libano 3
ME - Montenegro 3
NG - Nigeria 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
TH - Thailandia 3
TJ - Tagikistan 3
TT - Trinidad e Tobago 3
AD - Andorra 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BO - Bolivia 2
BS - Bahamas 2
BW - Botswana 2
BY - Bielorussia 2
CU - Cuba 2
DK - Danimarca 2
EE - Estonia 2
EU - Europa 2
Totale 21.298
Salva come PNG Salva come JPEG
Città #
Singapore 2.190
Hong Kong 948
Moscow 712
Hefei 681
Secaucus 458
Beijing 454
Chandler 453
Ashburn 368
Santa Clara 326
Millbury 269
Amsterdam 243
Munich 224
Los Angeles 190
Ho Chi Minh City 187
Jacksonville 160
Princeton 156
Naples 155
Dallas 124
Buffalo 123
Nanjing 116
Seoul 115
Redondo Beach 114
Hanoi 111
Dong Ket 98
Napoli 92
Wilmington 90
Helsinki 89
Boston 82
São Paulo 79
The Dalles 79
Des Moines 76
Kochi 74
New York 74
Ottawa 66
Nuremberg 64
Turku 57
Milan 53
Seattle 49
Lawrence 47
Mexico City 43
Nanchang 41
Frankfurt am Main 39
Montreal 39
Brooklyn 35
Chicago 35
Dublin 32
Johannesburg 32
Stockholm 32
Warsaw 30
London 28
Rio de Janeiro 28
Rome 28
Tianjin 27
Hebei 26
Belo Horizonte 25
Houston 25
Orem 24
Falkenstein 23
Shenyang 23
Haiphong 22
Poplar 22
Pune 22
Toronto 22
Vienna 22
Brasília 21
Jiaxing 21
Norwalk 21
Denver 19
Boardman 18
Atlanta 17
Phoenix 17
Tokyo 17
Chennai 16
Da Nang 15
Dhaka 15
Falls Church 15
Porto Alegre 15
Salerno 15
Biên Hòa 14
Ninh Bình 14
Hải Dương 13
Salvador 13
Amman 12
Manchester 12
Salt Lake City 12
Tashkent 12
Changsha 11
Charlotte 11
Curitiba 11
Düsseldorf 11
Guarulhos 11
Guayaquil 11
Kunming 11
Quito 11
San Francisco 11
Shanghai 11
Baghdad 10
Bắc Ninh 10
Asunción 9
Bologna 9
Totale 11.263
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 668
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells 241
Manuale di Oncologia Clinica 190
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 158
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 150
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 148
Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial 147
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 146
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 136
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 134
Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 123
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 122
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 122
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial 121
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 118
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 118
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial 117
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 115
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 115
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 114
An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer 114
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 113
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 113
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 112
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 111
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials 110
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 110
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 110
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 109
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 108
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 108
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 107
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 107
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series 106
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 105
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 105
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 104
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 104
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 103
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 103
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer 103
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 102
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 102
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 102
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 101
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 100
Amyloid in bone marrow smears of patients affected by multiple myeloma. 100
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 100
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 100
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 99
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 99
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 98
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 98
Targeting cell cycle in breast cancer: CDK4/6 inhibitors 97
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models 97
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 96
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 96
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 96
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 95
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients 95
Oleanolic Acid Modulates DNA Damage Response to Camptothecin Increasing Cancer Cell Death 93
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 93
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 93
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype 92
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 91
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 91
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 91
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. 90
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 90
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients 90
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 89
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 89
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results 89
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 88
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 88
Prognostic significance of multifocality in primary breast cancer. 88
TAG-72 expression and clinical outcome in primary breast cancer. 88
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 88
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 87
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 87
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 87
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 87
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy 87
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 86
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 86
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 86
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial 85
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin 84
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer 84
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo 84
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 84
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis 83
Uptake of trastuzumab biosimilars for the treatment of her2-positive breast cancer: A real-world experience from a cancer center 83
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. 83
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion 83
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 82
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 82
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial 81
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 81
Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement 81
Totale 10.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.276
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021414 0 0 0 0 0 78 49 11 101 17 50 108
2021/20221.110 9 4 10 4 21 50 15 45 175 90 202 485
2022/20231.339 224 95 38 79 129 123 12 80 189 248 100 22
2023/20241.156 43 166 161 77 50 79 13 81 12 22 198 254
2024/20257.458 457 582 42 75 150 343 752 490 791 821 2.276 679
2025/20268.801 1.507 1.765 1.505 1.294 2.221 509 0 0 0 0 0 0
Totale 21.790